| ADAR1-CAPITAL-MANAGEMENT |
ADAR1-CAPITAL-MANAGEMENT |
92%
|
with participation from new and existing investors, including ADAR1 Capital Management |
| AFFINITY-ASSET-ADVISORS |
AFFINITY-ASSET-ADVISORS |
92%
|
with participation from new and existing investors, including Affinity Asset Advisors |
| BALYASNY-ASSET-MANAGEMENT |
BALYASNY-ASSET-MANAGEMENT |
92%
|
with participation from new and existing investors, including Balyasny Asset Management |
| DRIEHAUS-CAPITAL-MANAGEMENT |
DRIEHAUS-CAPITAL-MANAGEMENT |
92%
|
with participation from new and existing investors, including Driehaus Capital Management |
| KALEHUA-CAPITAL |
KALEHUA-CAPITAL |
92%
|
with participation from new and existing investors, including Kalehua Capital |
| LYNX1-CAPITAL-MANAGEMENT |
LYNX1-CAPITAL-MANAGEMENT |
92%
|
with participation from new and existing investors, including Lynx1 Capital Management |
| NANTAHALA-CAPITAL |
NANTAHALA-CAPITAL |
92%
|
with participation from new and existing investors, including Nantahala Capital |
| NEW-ENTERPRISE-ASSOCIATES |
NEW-ENTERPRISE-ASSOCIATES |
92%
|
with participation from new and existing investors, including New Enterprise Associates |
| NOVO-NORDISK |
NOVO-NORDISK |
92%
|
The Company assessed this arrangement in accordance with ASC Topic 606, Revenue from Contracts with Customers, and concluded that the contract counterparty, Novo Nordisk, is a customer. |
| VENROCK-HEALTHCARE-CAPITAL-PARTNERS |
VENROCK-HEALTHCARE-CAPITAL-PARTNERS |
92%
|
The private placement was led by Venrock Healthcare Capital Partners, with participation from new and existing investors |
| NVO |
Novo Nordisk A/S |
72%
|
Reciprocal relationship from NVO graph: Reciprocal relationship from KRRO graph: Reciprocal relationship from NVO graph: Reciprocal relationship from KRRO graph: g placement agent fees and offering e… |
| NVO |
Novo Nordisk A/S |
72%
|
g placement agent fees and offering expenses of approximately $ 4.7 million. The pre-funded warrants have an exercise price of $ 0.001 per share. No pre-funded warrants have been exercised as of Marc… |
| FREQUENCY-THERAPEUTICS-INC |
FREQUENCY-THERAPEUTICS-INC |
62%
|
elaware corporation and in November 2023 completed a reverse merger with its now wholly-owned subsidiary and changed its name from Frequency Therapeutics, Inc. (“Frequency”) to Korro Bio, Inc. The Co… |
| GENEVANT-SCIENCES-GMBH |
GENEVANT-SCIENCES-GMBH |
62%
|
g placement agent fees and offering expenses of approximately $ 4.7 million. The pre-funded warrants have an exercise price of $ 0.001 per share. No pre-funded warrants have been exercised as of Marc… |
| KORRO-BIO-OPS-INC |
KORRO-BIO-OPS-INC |
62%
|
g placement agent fees and offering expenses of approximately $ 4.7 million. The pre-funded warrants have an exercise price of $ 0.001 per share. No pre-funded warrants have been exercised as of Marc… |
| K-SMALLER-REPORTING-COMPANY |
K-SMALLER-REPORTING-COMPANY |
62%
|
on, we have funded our operations primarily through proceeds from the issuance of convertible preferred stock and common stock. To date, we have raised approximately $223.6 million of aggregate gross… |
| USA-LLC |
USA-LLC |
62%
|
me generated from a lower cash, cash equivalent and marketable securities balance during the quarter prior to the March 2026 PIPE. Liquidity and Capital Resources Sources of Liquidity Since our incep… |
